• New Quebec concept aims to replace multiculturalism: Interculturalism (The Globe and Mail), http://ow.ly/49aNC #
  • Patent Expirations Threaten Drug Industry Profits (NY Times), http://ow.ly/49brM #
  • Canadian equity market beats emerging nations (The Globe and Mail), http://ow.ly/49buM #
  • How Apple handled the iPhone 4 crisis (The Globe and Mail), http://ow.ly/49bwS #
  • Merck and Lycera collaborate to treat autoimmune diseases (NJ.com), http://ow.ly/49dKg #
  • Traditional drug-discovery model ripe for reform: Proposals for collaborative research gain traction (Nature News), http://ow.ly/49dLk #
  • Sunny with not a cloud in the sky. Great way to start the week. #
  • Blocking agents help overcome immune rejection of stem cells in mice (Press Association), http://ow.ly/49dMj #
  • Hepregen launches first drug safety product, platform tests drugs for liver toxicity (Boston Business Journal), http://ow.ly/49dNO #
  • Charles River to distribute Pfizer's animal models to researchers (Mass High Tech), http://ow.ly/49dP5 #
  • FDA gives orphan-drug designation to an Infinity cancer drug (Mass High Tech), http://ow.ly/49dQj #
  • FDA agrees with Allos' design for a Phase III trial of Folotyn (Reuters), http://ow.ly/49dRE #
  • Quebec's research ambitions: Some science fields in the province are booming; others are stagnating (Nature), http://ow.ly/49o3X #
  • BioTech Montréal – Prochain Événement / Next Event – 15/03/2011 – Café Melies – RSVP: http://ow.ly/45tUe #

Comments are closed.